Multiple Sclerosis Drugs

In your trust how many patients with Multiple Sclerosis have been treated with MS disease modifying drugs in the past 6 months, latest 6 months that you can provide.

Please provide the number of patients by treatment for the following disease modifying drugs.

Aubagio (teriflunomide)

Avonex (interferon beta-1a)

Betaferon (interferon beta-1b)

Copaxone (glatiramer acetate)

Extavia (beta interferon-1b)

Gilenya (fingolimod)

Lemtrada (alemtuzumab)

Rebif (beta interferon-1a)

Tecfidera (dimethyl fumarate)

Tysabri (natalizumab)

Ampyra (Fampyra)

Peginterferon beta-1a (Plegridy)

Daclizumab (Zinbryta)

Others

 

In the table below please find the total number of patients under the care of Neurology who have been treated with each of the drugs listed in the last 6 months for any indication. The total number of patients under the care of Neurology treated with the agents is listed as the Trust does not record the indication for treatment on the Pharmacy dispensing system. The data may, therefore, include patients who have been treated with these drugs for other indications. Where a drug is not listed it is because the Trust has not used it in the time period specified.

 

DRUG Patients
DIMETHYL FUMARATE 15
FINGOLIMOD 5
HOMECARE INTERFERON BETA-1A (AVONEX) 6
HOMECARE INTERFERON BETA-1A (REBIJECT) 2
HOMECARE INTERFERON BETA-1A (REBISMART) 12
HOMECARE INTERFERON BETA-1A (REBISMART) INITIATION PACK 1
HOMECARE INTERFERON BETA-1B (BETAFERON) CONTINUATION PACK 3

©2017 Royal Surrey County Hospital

Log in with your credentials

or    

Forgot your details?